Assessing our smoke-free products
Cigarette smoke has been well characterized, with more than 6,000 constituents identified. Within this complex mixture, about 100 constituents have been associated with smoking-related disease by public health authorities and are known as harmful and potentially harmful constituents (HPHCs). Scientifically substantiated smoke-free products have a potentially valuable role to play because they emit or release much lower levels of HPHCs than cigarettes. Our aim at PMI is to reduce and, if possible, completely eliminate the presence of HPHCs emitted or released by our smoke-free products.
We conduct a robust approach when assessing our smoke-free products. At each step of our assessment program, scientific rigor is applied. As such, we follow recognized scientific standards, guidelines, and practices. We also prioritize transparency and openly share our research and findings in peer-reviewed journals.
When it comes to our aerosol studies, we use HPHC lists to measure our progress of eliminating or reducing the presence of toxicants emitted by our smoke-free products, as well as to satisfy regulatory requirements worldwide. Some of the lists we use include the U.S. Food and Drug Administration (FDA)’s 2012 list which comprises of HPHCs to be measured and reported in either cigarette smoke, smokeless tobacco, or roll-your-own tobacco and cigarette filler, or the Health Canada list, currently the most extensive active regulatory reporting list for cigarette smoke constituents worldwide. We have also developed an internal list, the PMI-58 list, where we prioritize 58 constituents and analytes representing all major toxicologically relevant chemical classes of compounds present in both the particulate and gas-vapor phases of cigarette smoke.